Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670160 | 0.85 | ALDH1A1 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL2670129 | 0.81 | KMT2A (0.44) | SMYD2CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL4748631 | 0.78 | KMT2A (0.41) | CYP3A4KMT2AHSD11B1 | |
| SCHEMBL4748644 | 0.78 | KMT2A (0.39) | KMT2AHSD11B1 | |
| SCHEMBL4792235 | 0.71 | KMT2A (0.31) | KMT2A | |
| SCHEMBL10289647 | 0.69 | KMT2A (0.35) | KMT2AHSD11B1 | |
| SCHEMBL10289932 | 0.69 | KMT2A (0.37) | CYP3A4KMT2AHSD11B1 | |
| SCHEMBL13652965 | 0.68 | KMT2A (0.46) | KMT2AHSD11B1 | |
| SCHEMBL17184756 | 0.67 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL12167674 | 0.66 | KMT2A (0.43) | KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | SMYD2 2578/4885CYP3A4 153/4885HTT 4836/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | SMYD2 2578/4885CYP3A4 153/4885HTT 4836/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | SMYD2 2578/4885CYP3A4 153/4885HTT 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.